Georgetown University

Running trials

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

  NCT07188896· Phase 2· Brian Rini· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT07154290· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

  NCT07128199· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

  NCT06853925· Georgetown University· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· ACADIA Pharmaceuticals Inc.· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Rapamycin Holdings Inc.· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

  NCT06808984· Phase 2· Celgene· Source

• Recruiting

  The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

  NCT06892275· Georgetown University· Source

• Recruiting

  Mosaic Trial for Stem Cell Transplant Recipients

  NCT06960993· Northwestern University· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  ASSESS ALL ALS Study

  NCT06578195· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Recruiting

  Gilteritinib for the Treatment of ALK NSCLC

  NCT06225427· Phase 1· University of Michigan Rogel Cancer Center· Source

• Active, not recruiting

  PREVENT ALL ALS Study

  NCT06581861· St. Joseph's Hospital and Medical Center, Phoenix· Source

• Recruiting

  Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

  NCT05655325· Columbia University· Source

• Active, not recruiting

  A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

  NCT06285643· Phase 2· AskBio Inc· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Active, not recruiting

  TheraSphere With Durvalumab and Tremelimumab for HCC

  NCT05063565· Phase 2· Boston Scientific Corporation· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Alzheimer's Plasma Extension

  NCT06416072· University of Southern California· Source

• Active, not recruiting

  The BD Liverty™ TIPS Stent Graft Study

  NCT05711316· C. R. Bard· Source

• Recruiting

  Lupus Landmark Study: A Prospective Registry and Biorepository

  NCT05934149· Lupus Research Alliance· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

  NCT05531656· Phase 2· Cognition Therapeutics· Source

• Enrolling by invitation

  Alzheimer's Disease Neuroimaging Initiative 4

  NCT05617014· University of Southern California· Source

• Recruiting

  Clinical Trial of Approaches to Prostate Cancer Surgery

  NCT05155501· Weill Medical College of Cornell University· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Emicizumab in Patients With Acquired Hemophilia A

  NCT05345197· Phase 2· University of Washington· Source

• Enrolling by invitation

  Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

  NCT05529342· American Gene Technologies International Inc.· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Synthekine· Source

• Active, not recruiting

  A Study of NDI 1150-101 in Patients With Solid Tumors

  NCT05128487· Phase 1/2· Nimbus Saturn, Inc.· Source

• Active, not recruiting

  Intervention-Induced Plasticity of Flexibility and Learning Mechanisms in ASD

  NCT05131659· Children's National Research Institute· Source

• Recruiting

  Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  NCT04886804· Phase 1· Boehringer Ingelheim· Source

• Recruiting

  Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

  NCT05137665· Target ALS Foundation, Inc.· Source

• Active, not recruiting

  Metformin in Alzheimer's Dementia Prevention

  NCT04098666· Phase 2/3· Columbia University· Source

• Active, not recruiting

  Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

  NCT04624204· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

  NCT04398628· American Thrombosis and Hemostasis Network· Source

• Active, not recruiting

  AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

  NCT04468659· Phase 3· Eisai Inc.· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

  NCT03932201· Bayer· Source

• Active, not recruiting

  Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT03909334· Phase 2· Xiuning Le· Source

• Active, not recruiting

  Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

  NCT03971409· Phase 2· Laura Huppert, MD, BA· Source

• Active, not recruiting

  Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

  NCT03554356· University of North Carolina, Chapel Hill· Source

• Active, not recruiting

  Spinraza in Adult Spinal Muscular Atrophy

  NCT03709784· Washington University School of Medicine· Source

• Active, not recruiting

  Longitudinal Early-onset Alzheimer's Disease Study Protocol

  NCT03507257· Indiana University· Source

Showing 50 of 56.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer5 recruiting
• Huntington's disease4 recruiting
• Alzheimer disease3 recruiting
• ALS (motor neurone disease)2 recruiting
• HIV2 recruiting
• Lewy body dementia2 recruiting
• Chronic kidney disease1 recruiting
• Frontotemporal dementia1 recruiting
• Haemophilia1 recruiting
• Kidney cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Sickle cell disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thalassaemia1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Terminated

  BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

  NCT06611436· Phase 1/2· Be Biopharma· Source

• Completed

  Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

  NCT05644262· Phase 2· University of Southern California· Source

• Completed

  Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

  NCT05896852· Georgetown University· Source

• Terminated

  Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

  NCT05980416· Phase 1· Elevation Oncology· Source

• Terminated

  A Study to Investigate LYL845 in Adults With Solid Tumors

  NCT05573035· Phase 1· Lyell Immunopharma, Inc.· Source

• Completed

  PositiveLinks: mHealth for DC Cohort

  NCT04998019· George Washington University· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

  NCT05495243· Phase 2· Renovion, Inc.· Source

• Completed

  A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.

  NCT05924243· Phase 1· Hoffmann-La Roche· Source

• Completed

  STEM-Parkinson's Disease

  NCT04797611· Scion NeuroStim· Source

• Terminated

  A Study to Investigate LYL797 in Adults With Solid Tumors

  NCT05274451· Phase 1· Lyell Immunopharma, Inc.· Source

• Terminated

  Next-Gen MS: Feed-forward PRO Data for MS Research

  NCT04907305· EMD Serono Research & Development Institute, Inc.· Source

• Terminated

  Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

  NCT04849364· Phase 2· Bryan Schneider, MD· Source

• Completed

  SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

  NCT04381468· Phase 1/2· Vaccinex Inc.· Source

• Completed

  PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

  NCT04815876· Weill Medical College of Cornell University· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  The MS-LINK™ Outcomes Study

  NCT04735406· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy

  NCT04843566· Weill Medical College of Cornell University· Source

• Completed

  KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)

  NCT04165083· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

  NCT04383210· Phase 2· Elevation Oncology· Source

• Terminated

  A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

  NCT04494256· Phase 1/2· Biogen· Source

• Completed

  Human Epilepsy Project 3

  NCT05374928· NYU Langone Health· Source

• Completed

  Lu AF28996 in Participants With Parkinson's Disease (PD)

  NCT04291859· Phase 1· H. Lundbeck A/S· Source

• Completed

  KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

  NCT04165096· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

  NCT04165070· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

  NCT04165798· Merck Sharp & Dohme LLC· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· University of Southern California· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

  NCT03552380· Phase 2· Roberto Pili· Source

• Completed

  Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

  NCT03500328· Johns Hopkins University· Source

• Completed

  A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

  NCT03456063· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

  NCT03586297· Hackensack Meridian Health· Source

• Completed

  Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

  NCT03117309· Phase 2· Michael B. Atkins, MD· Source

• Completed

  Memory Improvement Through Nicotine Dosing (MIND) Study

  NCT02720445· Phase 2· University of Southern California· Source

• Completed

  Alzheimer's Disease Neuroimaging Initiative 3

  NCT02854033· University of Southern California· Source

• Completed

  A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

  NCT02017717· Phase 3· Bristol-Myers Squibb· Source

Conditions

Diseases this institution publishes on or runs trials for.

• HIV120 works · 4 trials
• Amyloidosis17 works · 0 trials
• Spinal cord injury15 works · 0 trials
• Hepatitis C12 works · 0 trials
• Hidradenitis suppurativa12 works · 0 trials
• Thyroid cancer9 works · 1 trial
• Huntington's disease9 works · 5 trials
• Sarcoidosis9 works · 0 trials
• Graves' disease and hyperthyroidism6 works · 0 trials
• Immune thrombocytopenia (ITP)5 works · 0 trials
• Vitiligo5 works · 0 trials
• Alopecia areata4 works · 0 trials